Allegheny General is one of more than 200 sites across 17 countries around the world involved in the C. diff vaccine clinical trial, a Phase III randomized, observer-blind, placebo-controlled study.
Patients interested in enrolling in the study should be age 50 or older and planning an upcoming hospitalization of more than 72 hours for a surgical procedure. Also eligible for the study are patients in this age group who have been hospitalized at least twice, each time lasting more than 24 hours, and have received systemic antibiotics in the past year.
For more information about how to enroll, click here.
More articles on C. diff:
How South Seminole Hospital cut C. diff infections in half
10 recent stories, studies on C. diff
A non-antibiotic drug could work against C. diff, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
